Serumβ2-microglobulin in malignant lymphoma

Hagberg, Hans; Killander, A.; Simonsson, Bengt

doi:10.1002/1097-0142(19830615)51:12<2220::aid-cncr2820511212>3.0.co;2-a

Cited by 77 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The considerably lower risk of recurrence and longer duration of remission in patients with normal P-2 microglobulin levels also accord with the results of previous smaller studies (Hagberg et al, 1983). Once again it may be postulated that this relates to the effectiveness of host immune surveillance.…”

Section: Resultssupporting

confidence: 87%

“…Previous studies in non-Hodgkin's lymphoma have shown a correlation between stage of disease and P-2 microglobulin level (Spati et al, 1978;Child et al, 1980;Hagberg et al, 1983;Legros et al, 1987) (Moller et al, 1986), and that changes in HLA complex proteins which impair light and heavy chain association result in enhanced release of P-2 microglobulin (Ferrier et al, 1985;Rein et al, 1987).…”

Section: Resultsmentioning

confidence: 98%

“…As the light chain common to the major histocompatability (HLA) antigens A, B and C (Cresswell et al, 1974) it is shed into the circulation at a rate determined by lymphocyte activation and proliferation (Azocar et al, 1982). Studies in multiple myeloma have confirmed its usefulness as an independent prognostic marker (Bataille et al, 1983) whilst in non-Hodgkin's lymphoma levels have been correlated with extent of disease, response to chemotherapy and survival (Spati et al, 1978;Child et al, 1980;Hagberg et al, 1983;Legros et al, 1987). Recently it has been suggested that a serologic staging system based upon P-2 microglobulin and lactate dehydrogenase (LDH) levels may identify sub-groups with differing disease-free and overall survival more distinctly than conventional staging by the Ann Arbor criteria (Swan et al, 1989).…”

mentioning

confidence: 99%

See 2 more Smart Citations

β-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

Johnson

Whelan²,

Longhurst³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

beta-2 microglobulin levels were measured in stored serum taken at presentation from 262 patients treated with combination chemotherapy for Kiel classification high-grade lymphoma at a single centre over a 15 year period. A significant association was found between elevated levels and advanced (Ann Arbor stage III or IV) disease or hepatic infiltration, but not with other sites of extranodal involvement or bulky disease. Patients with normal levels at presentation had a 70% remission rate with treatment compared to 37% of those with elevated levels (P < 0.001). With median follow up of 6 years duration of remission was significantly greater in patients with normal beta-2 microglobulin at presentation (plateau at 70%, compared to median remission of 19 months in those with raised levels, P < 0.001). Survival overall was also better in the group with normal levels (actuarial median 9 years compared to 1 year, P < 0.001). Multivariate analyses including treatment type, age, sex, B symptoms, stage, bulk, albumin, sodium, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase and beta-2 microglobulin, placed beta-2 microglobulin among the three most influential independent variables for prediction of response rate, duration of remission and overall survival.

show abstract

Section: Resultssupporting

confidence: 87%

Section: Resultsmentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

β-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

Johnson

Whelan²,

Longhurst³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…This may be due to more active cellular proliferation in tumours with poorer histological differentiation. Similar findings however were not evident in non-Hodgkin's lymphoma (Anderson et al, 1983 (Teasdal et al, 1977) and myeloma (Hagberg et al, 1983;Alexanian et al, 1985), and is thought to be due to increased cell turnover (Karlsson et al, 1980) and/or augmented immune response by lymphocytes to the neoplasm (Forman, 1982;Rashid et al, 1980;Karlsson et al, 1980;Shuster et al, 1976).…”

mentioning

confidence: 86%

“…Cell membrane turnover is the principle source of P2M in blood, plasma and body fluids (Cresswell et al, 1974;Forman, 1982). Elevated serum levels has been found to be associated with increasing age, renal impairment (Bailey et al, 1978) and a variety of malignancies and appears to be a reflection of tumour load in patients with lymphoma (Anderson et al, 1983;Hagberg et al, 1983), myeloma (Child et al, 1983;Norfolk et al, 1980;Alexanian et al, 1985), lung cancer (Schweiger & Tocsanyi, 1978), breast cancer (Teasdal et al, 1977;Rashid et al, 1980), and squamous cell carcinoma of the head and neck (Wennerberg et al, 1984 (Ho et al, 1976). Although P2M has a high sensitivity in metastatic disease, the clinical relevance in this situation is limited.…”

mentioning

confidence: 99%

Expression of beta-2-microglobulin by nasopharyngeal carcinoma

Shiu

Leung²,

Leung³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

SummarySerum beta-2-microglobulin (02M) levels of 274 Chinese patients with different stages of nasopharyngeal carcinoma at presentation and that of 35 patients who developed distant metastases posttreatment were assayed. P2M level was found to increase with advancing stage of disease, with statistically significant differences among early-stage, advanced-stage, and metastatic disease. Elevated pre-treatment P2M levels were expressed more frequently by tumours with lower degree of histological differentiation. The sensitivity of serum P2M for diagnosis of nasopharyngeal carcinoma, however, is low.

show abstract

Serum β2 microglobulin in malignant lymphoproliferative disorders

Constantinides

Pathouli

Karvountzis

et al. 1985

Cancer

View full text Add to dashboard Cite

Serum beta‐2‐microglobulin (S‐β2M) was measured at diagnosis in 44 patients with lymphocytic leukemias and 47 with malignant lymphomas. Among patients with chronic lymphocytic leukemia (CLL) S‐β2M was raised (>3 mg/1) in 74% and in 23.5% of those with acute lymphoblastic leukemia (ALL). The frequencies for non‐Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) were 59.2% and 40%, respectively. In CLL patients high serum values correlated with large tumor mass, as estimated by Rai's clinical criteria (P < 0.001), by total peripheral lymphocytes (r = 0.41, P < 0.05) and by the percentage of bone marrow infiltration of the lymphocytes (P < 0.01). A significant relation was also found in CLL patients between S‐β2M level and survival (P < 0.05). In ALL no association was found between S‐β2M level with peripheral lymphoblast concentration, French‐American‐British (FAB) subclassification, splenomegaly, and survival. In NHL patients a significant association was found between S‐β2M levels and stage of disease (P < 0.01) and an obscure relation (P < 0.01) and an obscure relation (P < 0.1) with the presence of lymph nodes greater than 3 cm in diameter, splenomegaly, and hepatomegaly. No significant association was found between S‐β2M level and histologic subtypes, presence of B symptoms, bone marrow involvement, and survival. In HD patients a significant association was found between the level of S‐β2M and stage of disease (P < 0.05) and presence of splenomegaly (P < 0.05). No association was found between S‐β2M level and histologic subtypes, lymph nodes greater than 3 cm in diameter, bone marrow involvement, and B symptoms. A significant relation was found between S‐β2M level and survival in HD patients with widespread disease (P < .025).

show abstract

Serumβ2-microglobulin in malignant lymphoma

Cited by 77 publications

References 18 publications

β-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

β-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

Expression of beta-2-microglobulin by nasopharyngeal carcinoma

Serum β2 microglobulin in malignant lymphoproliferative disorders

Contact Info

Product

Resources

About